EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Myopia control in Mendelian forms of myopia

Emilie van der Sande iD, Jan Roelof Polling, J Willem L Tideman iD, Magda A Meester-Smoor, Alberta A H J Thiadens, Emily Tan iD, Chris I De Zeeuw, Ralph Hamelink, Ingo Willuhn, Virginie J M Verhoeven, Beerend H J Winkelman, Caroline C W Klaver

Ophthalmic and Physiological Optics · 2023

DOI: 10.1111/opo.13115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ophthalmic and Physiological Optics, 2023. Verfasst von Emilie van der Sande und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department Ophthalmology, Erasmus Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Atropine, Myopia, Degenerative. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 European Research Council, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To study the effectiveness of high‐dose atropine for reducing eye growth in Mendelian myopia in children and mice.

Methods

We studied the effect of high‐dose atropine in children with progressive myopia with and without a monogenetic cause. Children were matched for age and axial length (AL) in their first year of treatment. We considered annual AL progression rate as the outcome and compared rates with percentile charts of an untreated general population. We treated C57BL/6J mice featuring the myopic phenotype of Donnai–Barrow syndrome by selective inactivation of Lrp2 knock out (KO) and control mice (CTRL) daily with 1% atropine in the left eye and saline in the right eye, from postnatal days 30–56. Ocular biometry was measured using spectral‐domain optical coherence tomography. Retinal dopamine (DA) and 3,4‐dihydroxyphenylacetic acid (DOPAC) were measured using high‐performance liquid chromatography.

Results

Children with a Mendelian form of myopia had average baseline spherical equivalent (SE) –7.6 ± 2.5D and AL 25.8 ± 0.3 mm; children with non‐Mendelian myopia had average SE −7.3 ± 2.9 D and AL 25.6 ± 0.9 mm. During atropine treatment, the annual AL progression rate was 0.37 ± 0.08 and 0.39 ± 0.05 mm in the Mendelian myopes and non‐Mendelian myopes, respectively. Compared with progression rates of untreated general population (0.47 mm/year), atropine reduced AL progression with 27% in Mendelian myopes and 23% in non‐Mendelian myopes . Atropine significantly reduced AL growth in both KO and CTRL mice (male, KO: −40 ± 15; CTRL: −42 ± 10; female, KO: −53 ± 15; CTRL: −62 ± 3 μm). The DA and DOPAC levels 2 and 24 h after atropine treatment were slightly, albeit non‐significantly, elevated.

Conclusions

High‐dose atropine had the same effect on AL in high myopic children with and without a known monogenetic cause. In mice featuring a severe form of Mendelian myopia, atropine reduced AL progression. This suggests that atropine can reduce myopia progression even in the presence of a strong monogenic driver.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtropineMyopia, DegenerativeHumansMaleFemaleAnimalsMice3,4-Dihydroxyphenylacetic AcidMice, Inbred C57BLRefraction, OcularRetinaDisease ProgressionOphthalmic Solutions

Stichwörter der Autor:innen

Mendelian myopiaatropinedopaminelipoprotein receptor-related protein 2 knockout mousemyopia controlsyndromic myopia

Substanzen

3,4-Dihydroxyphenylacetic AcidAtropineOphthalmic Solutions

Autor:innen und Institutionen

  • Department Ophthalmology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Department Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Netherlands Institute for Neuroscience, Amsterdam, The Netherlands.
  • Departments Orthoptics and Optometry, Hogeschool Utrecht, Utrecht, The Netherlands.
  • Department Ophthalmology, Martini Hospital, Groningen, The Netherlands.
  • Department Neuroscience, Erasmus Medical Center, Rotterdam, The Netherlands.

ORCID-Profile: Emilie van der Sande, J Willem L Tideman, Emily Tan

Förderung

  • H2020 European Research Council
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • ZonMw

Zitieren

APA

van der Sande, E., Polling, J. R., Tideman, J. W. L., Meester-Smoor, M. A., Thiadens, A. A. H. J., Tan, E., De Zeeuw, C. I., Hamelink, R., Willuhn, I., Verhoeven, V. J. M., Winkelman, B. H. J., & Klaver, C. C. W. (2023). Myopia control in Mendelian forms of myopia. Ophthalmic and Physiological Optics. https://doi.org/10.1111/opo.13115

Vancouver

van der Sande E, Polling JR, Tideman JWL, Meester-Smoor MA, Thiadens AAHJ, Tan E, et al. Myopia control in Mendelian forms of myopia. Ophthalmic and Physiological Optics. 2023. doi:10.1111/opo.13115

BibTeX
@article{vanderSande2023,
  author = {van der Sande, Emilie and Polling, Jan Roelof and Tideman, J Willem L and Meester-Smoor, Magda A and Thiadens, Alberta A H J and Tan, Emily and De Zeeuw, Chris I and Hamelink, Ralph and Willuhn, Ingo and Verhoeven, Virginie J M and Winkelman, Beerend H J and Klaver, Caroline C W},
  title = {Myopia control in Mendelian forms of myopia},
  journal = {Ophthalmic and Physiological Optics},
  year = {2023},
  doi = {10.1111/opo.13115}
}
Kostenlos starten →